Pregabalin:: A novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders
Pregabalin:: A novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders
复制标题
DOI：
10.1016/j.clinthera.2007.01.013
复制
发表时间：
2007-01-01
影响因子：
3.2
通讯作者：
Nuzum, Donald
中科院分区：
文献类型：
--
作者：
Tassone, Daniel M.;Boyce, Eric;Nuzum, Donald
背景资料：美国食品和药物管理局（FDA）于2004年12月批准普瑞巴林用于治疗与糖尿病周围神经病变和带状疱疹后神经痛相关的神经性疼痛。普瑞巴林是第一个在美国和欧洲批准用于这两种情况的药物。2005年6月，普瑞巴林被批准作为成人部分性癫痫发作的预防性治疗。FDA目前正在考虑批准普瑞巴林作为广泛性焦虑症（GAD）或社交焦虑症（SAD）成人的预防治疗。目的：本综述的目的是总结普瑞巴林的药理学、药代动力学、疗效和耐受性;回顾其在神经性疼痛和难治性部分发作性癫痫发作管理中的批准用途;并研究其在GAD或SAD患者中的潜在用途。通过检索MEDLINE确定相关英文文献（1993- 2006年6月）和国际药物文摘（2000- 2006年6月）。检索词包括普瑞巴林、Lyrica、S-（+）-3异丁基GABA、PN、DPN、糖尿病周围神经病变、PHN、带状疱疹后神经痛、部分性癫痫发作、癫痫、广泛性焦虑症和CI-1008。在总共1068例糖尿病周围神经病变患者的4项临床试验中，接受普瑞巴林300 - 600 mg/d治疗的患者的平均疼痛评分比接受安慰剂治疗的患者显著改善（P
Background: The US Food and Drug Administration (FDA) approved pregabalin in December 2004 for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. Pregabalin is the first drug approved in the United States and in Europe for both conditions. In June 2005, pregabalin was approved as an adjunctive treatment in adults with partial-onset seizures. The FDA currently is considering the approval of pregabalin as adjunctive therapy in adults with generalized anxiety disorder (GAD) or social anxiety disorder (SAD). Objectives: The goals of this review were to summarize the pharmacology, pharmacokinetics, efficacy, and tolerability of pregabalin; review its approved uses in the management of neuropathic pain and refractory partial-onset seizures; and investigate its potential use in patients with GAD or SAD.Methods: Relevant English-language literature was identified through a search of MEDLINE (1993-June 2006) and International Pharmaceutical Abstracts (2000-june 2006). The search terms included pregabalin, Lyrica, S-(+)-3 isobutylgaba, PN, DPN, diabetic peripheral neuropathy, PHN, postherpetic neuralgia, partial seizures, epilepsy, generalized anxiety disorder, and CI-1008.Results: In 4 clinical trials in a total of 1068 patients with diabetic peripheral neuropathy, the patients receiving pregabalin 300 to 600 mg/d had significantly greater improvement in mean pain scores than placebo recipients (P